Jpmorgan Chase & CO Eiger Bio Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Dec 26, 2024	BUY	$0.21 - $0.43 $34 - $71	166 New	166 $0
Q4 2023 Feb 12, 2024	SELL	$0.21 - $0.43 $1,730 - $3,544	-8,242 Reduced 98.03%	166 $0
Q3 2023 Nov 14, 2023	SELL	$0.28 - $0.93 $37,900 - $125,884	-135,360 Reduced 94.15%	8,408 $2,000
Q2 2023 Aug 11, 2023	SELL	$0.55 - $1.26 $47,794 - $109,492	-86,899 Reduced 37.67%	143,768 $100,000
Q1 2023 May 18, 2023	BUY	$0.89 - $2.52 $28,420 - $80,471	31,933 Added 16.07%	230,667 $207,000
Q1 2023 May 11, 2023	BUY	$0.89 - $2.52 $76,720 - $217,231	86,203 Added 76.6%	198,734 $178,000
Q4 2022 Feb 13, 2023	SELL	$1.02 - $7.48 $1,917 - $14,062	-1,880 Reduced 1.64%	112,531 $133,000
Q3 2022 Nov 14, 2022	SELL	$6.04 - $9.66 $1,491 - $2,386	-247 Reduced 0.22%	114,411 $862,000
Q2 2022 Aug 11, 2022	BUY	$4.99 - $8.96 $12,659 - $22,731	2,537 Added 2.26%	114,658 $722,000
Q1 2022 May 11, 2022	SELL	$3.84 - $9.74 $11,458 - $29,064	-2,984 Reduced 2.59%	112,121 $931,000
Q4 2021 Feb 10, 2022	SELL	$5.12 - $8.19 $4,981 - $7,968	-973 Reduced 0.84%	115,105 $598,000
Q3 2021 Nov 12, 2021	BUY	$6.68 - $9.1 $775,401 - $1.06 Million	116,078 New	116,078 $775,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.